Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Jennifer Diamond

Concepts (284)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Triple Negative Breast Neoplasms
16
2024
191
6.650
 Why?
Breast Neoplasms
23
2023
2132
4.380
 Why?
Immunoconjugates
7
2023
101
2.600
 Why?
Antineoplastic Agents
23
2023
2051
2.600
 Why?
Antineoplastic Combined Chemotherapy Protocols
19
2023
1559
2.460
 Why?
Pyrimidines
9
2021
445
2.400
 Why?
Receptor, ErbB-2
11
2023
325
1.950
 Why?
Protein Kinase Inhibitors
10
2022
872
1.730
 Why?
Piperazines
4
2020
336
1.690
 Why?
Paclitaxel
6
2022
214
1.620
 Why?
Camptothecin
9
2023
106
1.600
 Why?
Neoplasms
14
2022
2464
1.600
 Why?
Pyrazoles
6
2021
404
1.390
 Why?
Quinoxalines
2
2020
65
1.310
 Why?
Antibodies, Monoclonal, Humanized
10
2024
755
1.290
 Why?
Azepines
3
2020
88
1.250
 Why?
Ovarian Neoplasms
4
2020
488
1.220
 Why?
Histone Deacetylase Inhibitors
4
2024
207
1.210
 Why?
Cyclin-Dependent Kinase 4
2
2018
42
1.110
 Why?
Cyclin-Dependent Kinase 6
2
2018
39
1.100
 Why?
Neutropenia
4
2022
134
0.890
 Why?
Gene Expression Regulation, Neoplastic
5
2020
1351
0.790
 Why?
Xenograft Model Antitumor Assays
11
2021
814
0.760
 Why?
beta Catenin
2
2020
219
0.760
 Why?
Breast Neoplasms, Male
2
2018
29
0.740
 Why?
Female
49
2024
68153
0.700
 Why?
Cancer Care Facilities
1
2020
32
0.690
 Why?
Chemotherapy, Adjuvant
4
2023
376
0.690
 Why?
Maximum Tolerated Dose
9
2022
192
0.690
 Why?
Benzoxazoles
1
2020
19
0.690
 Why?
Receptors, Estrogen
3
2021
424
0.680
 Why?
Carcinoma, Lobular
2
2018
48
0.680
 Why?
eIF-2 Kinase
1
2019
29
0.650
 Why?
Lymphocytes, Tumor-Infiltrating
2
2020
210
0.640
 Why?
Tumor Microenvironment
4
2024
623
0.630
 Why?
Anthracyclines
3
2023
46
0.610
 Why?
Humans
62
2024
128417
0.610
 Why?
Taxoids
3
2023
95
0.600
 Why?
Drug Resistance, Neoplasm
4
2020
749
0.580
 Why?
Wnt Signaling Pathway
1
2019
165
0.580
 Why?
Carcinoma, Ductal, Breast
1
2018
82
0.570
 Why?
Aurora Kinase A
4
2020
55
0.570
 Why?
Aged
22
2023
21953
0.560
 Why?
Trastuzumab
4
2023
100
0.560
 Why?
Pyrazines
2
2018
86
0.540
 Why?
Myocardial Infarction
1
2023
1015
0.520
 Why?
Colonic Neoplasms
1
2018
242
0.510
 Why?
Pyridines
2
2018
475
0.510
 Why?
Tumor Suppressor Protein p53
4
2024
508
0.500
 Why?
Neoadjuvant Therapy
1
2018
381
0.490
 Why?
Nuclear Proteins
2
2023
657
0.490
 Why?
Angiopoietin-1
1
2015
11
0.490
 Why?
Angiopoietin-2
1
2015
15
0.490
 Why?
Medicare
4
2023
715
0.450
 Why?
Uterine Cervical Neoplasms
1
2017
232
0.450
 Why?
Cell Line, Tumor
9
2022
3184
0.440
 Why?
Colorectal Neoplasms
5
2022
746
0.430
 Why?
Middle Aged
23
2021
30889
0.420
 Why?
Antibodies, Monoclonal
4
2024
1355
0.410
 Why?
Dose-Response Relationship, Drug
6
2022
1936
0.410
 Why?
Cell Proliferation
8
2020
2344
0.400
 Why?
Tumor Suppressor Proteins
1
2015
313
0.400
 Why?
Proto-Oncogene Proteins c-met
1
2013
74
0.400
 Why?
Antineoplastic Agents, Immunological
3
2019
175
0.400
 Why?
Recombinant Fusion Proteins
1
2015
634
0.390
 Why?
Point Mutation
1
2013
223
0.390
 Why?
Adult
24
2024
35299
0.390
 Why?
Treatment Outcome
12
2022
10151
0.390
 Why?
Triazoles
1
2013
147
0.380
 Why?
Angiogenesis Inhibitors
3
2018
215
0.370
 Why?
Mice, Nude
6
2020
682
0.360
 Why?
Carcinoma, Renal Cell
1
2013
179
0.360
 Why?
Mitochondria
1
2017
848
0.350
 Why?
Clinical Trials, Phase I as Topic
2
2020
50
0.350
 Why?
Neoplasm Recurrence, Local
4
2021
958
0.340
 Why?
Heart Failure
1
2023
2145
0.340
 Why?
Histones
3
2023
586
0.340
 Why?
Neoplasm Metastasis
4
2020
608
0.340
 Why?
Genes, BRCA2
1
2009
24
0.330
 Why?
Genes, BRCA1
1
2009
32
0.330
 Why?
Biomarkers, Tumor
2
2014
1181
0.330
 Why?
Molecular Targeted Therapy
3
2019
385
0.320
 Why?
Aged, 80 and over
8
2020
7033
0.320
 Why?
BRCA2 Protein
1
2009
53
0.320
 Why?
Thrombophilia
1
2009
66
0.310
 Why?
Pregnancy Complications, Neoplastic
1
2009
52
0.310
 Why?
Neoplasm Staging
5
2021
1290
0.310
 Why?
Lung Neoplasms
2
2024
2328
0.310
 Why?
Kidney Neoplasms
1
2013
349
0.310
 Why?
Apoptosis
7
2024
2435
0.310
 Why?
Quinolines
2
2021
153
0.300
 Why?
Aromatase Inhibitors
2
2018
51
0.300
 Why?
Receptors, Progesterone
2
2021
341
0.290
 Why?
DNA-Binding Proteins
1
2015
1421
0.280
 Why?
Mice
9
2021
16602
0.270
 Why?
Models, Biological
1
2014
1691
0.260
 Why?
Doxorubicin
3
2024
322
0.250
 Why?
Liver Neoplasms
1
2009
633
0.220
 Why?
Cyclophosphamide
2
2018
227
0.220
 Why?
Radiosurgery
2
2019
318
0.220
 Why?
Disease Models, Animal
3
2021
3937
0.220
 Why?
United States
5
2023
13830
0.210
 Why?
Animals
11
2021
34479
0.200
 Why?
Cyclin-Dependent Kinase 9
1
2022
10
0.200
 Why?
Biopsy
2
2018
1081
0.200
 Why?
Histone Deacetylase 1
1
2022
24
0.190
 Why?
Administration, Oral
3
2022
754
0.190
 Why?
Aurora Kinases
2
2012
29
0.190
 Why?
G2 Phase Cell Cycle Checkpoints
3
2022
45
0.190
 Why?
Disease Progression
4
2019
2602
0.190
 Why?
Topoisomerase I Inhibitors
2
2022
16
0.190
 Why?
Fluorouracil
1
2022
197
0.190
 Why?
Acetylation
1
2022
237
0.180
 Why?
Biliary Tract Neoplasms
1
2021
25
0.180
 Why?
Arrhythmias, Cardiac
1
2023
316
0.180
 Why?
Androstadienes
1
2021
106
0.180
 Why?
Diarrhea
2
2019
177
0.180
 Why?
Carboplatin
1
2021
140
0.180
 Why?
Heterografts
1
2021
129
0.170
 Why?
Necrosis
2
2019
229
0.170
 Why?
Drug Administration Schedule
3
2017
751
0.170
 Why?
Hospitals, University
1
2021
176
0.170
 Why?
Fatigue
2
2022
317
0.170
 Why?
Immunotherapy
2
2023
587
0.170
 Why?
Histone Deacetylases
1
2022
210
0.170
 Why?
Clinical Trials as Topic
3
2016
993
0.170
 Why?
Male
13
2021
62857
0.170
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
58
0.170
 Why?
Benzodiazepines
1
2021
129
0.170
 Why?
Immune System
1
2021
176
0.160
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2020
115
0.160
 Why?
Myeloid Cell Leukemia Sequence 1 Protein
1
2019
43
0.160
 Why?
Kaplan-Meier Estimate
1
2021
853
0.160
 Why?
Tumor Cells, Cultured
1
2020
930
0.150
 Why?
Albumins
1
2019
101
0.150
 Why?
Maintenance Chemotherapy
1
2018
22
0.150
 Why?
Aquaporin 4
1
2019
96
0.150
 Why?
Vascular Endothelial Growth Factor A
2
2018
500
0.150
 Why?
Aminopyridines
1
2018
96
0.150
 Why?
Nausea
1
2018
107
0.150
 Why?
Antibodies, Bispecific
1
2018
49
0.140
 Why?
Mice, Inbred BALB C
1
2020
1228
0.140
 Why?
Drug Therapy, Combination
1
2020
1009
0.140
 Why?
Breast
1
2018
152
0.140
 Why?
Radiotherapy, Adjuvant
1
2018
209
0.140
 Why?
Purines
1
2018
169
0.140
 Why?
Benzimidazoles
1
2018
157
0.140
 Why?
Mastectomy
1
2018
131
0.140
 Why?
Imidazoles
1
2018
226
0.140
 Why?
Topotecan
1
2017
12
0.140
 Why?
Isoflavones
1
2017
25
0.140
 Why?
Calcium-Binding Proteins
1
2018
210
0.140
 Why?
Survival Analysis
1
2020
1263
0.140
 Why?
Carbolines
1
2017
27
0.140
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2017
19
0.140
 Why?
Programmed Cell Death 1 Receptor
1
2019
228
0.130
 Why?
Inhibitory Concentration 50
2
2016
81
0.130
 Why?
Nanoparticles
1
2021
368
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
71
0.130
 Why?
Cell Survival
1
2019
1077
0.130
 Why?
Insulin-Like Growth Factor I
1
2018
307
0.130
 Why?
Hypertension
2
2018
1235
0.130
 Why?
GPI-Linked Proteins
1
2016
67
0.120
 Why?
Adaptor Proteins, Signal Transducing
1
2018
391
0.120
 Why?
Neoplasms, Second Primary
1
2016
108
0.120
 Why?
Tumor Protein p73
1
2015
14
0.120
 Why?
Antibodies, Neoplasm
1
2015
35
0.120
 Why?
Carcinoma, Non-Small-Cell Lung
1
2024
1045
0.120
 Why?
Phosphorylation
1
2019
1681
0.120
 Why?
Risk Reduction Behavior
1
2016
209
0.120
 Why?
Hodgkin Disease
1
2016
134
0.120
 Why?
Retrospective Studies
3
2021
14454
0.120
 Why?
Maytansine
1
2014
16
0.110
 Why?
Demography
1
2015
277
0.110
 Why?
Brain Edema
1
2014
60
0.110
 Why?
Drug Interactions
1
2015
357
0.110
 Why?
Survival Rate
2
2019
1869
0.110
 Why?
Protein Kinases
1
2015
309
0.110
 Why?
Randomized Controlled Trials as Topic
1
2019
1356
0.110
 Why?
Sulfones
1
2014
108
0.110
 Why?
Threonine
1
2013
44
0.110
 Why?
Drug Evaluation, Preclinical
1
2013
168
0.100
 Why?
Analgesics, Opioid
1
2021
887
0.100
 Why?
Glycine
1
2014
164
0.100
 Why?
Tumor Stem Cell Assay
1
2012
32
0.100
 Why?
Time Factors
2
2020
6482
0.100
 Why?
Drug Design
1
2013
154
0.100
 Why?
Methionine
1
2013
157
0.100
 Why?
Heterozygote
1
2013
267
0.100
 Why?
Disease-Free Survival
1
2014
647
0.100
 Why?
Treatment Failure
1
2013
339
0.100
 Why?
In Situ Hybridization, Fluorescence
1
2013
313
0.100
 Why?
Neovascularization, Pathologic
1
2013
290
0.090
 Why?
Computational Biology
1
2015
598
0.090
 Why?
Cluster Analysis
1
2012
478
0.090
 Why?
Cell Transformation, Neoplastic
1
2013
325
0.090
 Why?
Risk Assessment
1
2020
3232
0.090
 Why?
Receptor Protein-Tyrosine Kinases
1
2013
221
0.090
 Why?
Carcinoma in Situ
1
2011
45
0.090
 Why?
Cellular Senescence
1
2012
173
0.090
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2010
81
0.090
 Why?
Colorado
1
2020
4375
0.090
 Why?
Mutation
2
2012
3689
0.080
 Why?
Sequence Analysis, DNA
1
2013
771
0.080
 Why?
Brain Neoplasms
2
2019
1163
0.080
 Why?
Tumor Burden
1
2010
283
0.080
 Why?
Pregnancy Trimester, Second
1
2009
78
0.080
 Why?
Keratinocytes
1
2010
243
0.080
 Why?
Mastectomy, Segmental
1
2009
85
0.080
 Why?
Pregnancy Trimester, First
1
2009
138
0.080
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2009
90
0.080
 Why?
Apoptosis Regulatory Proteins
1
2009
182
0.080
 Why?
Lymph Node Excision
1
2009
165
0.070
 Why?
Risk
1
2009
853
0.070
 Why?
Infusions, Intravenous
2
2019
385
0.070
 Why?
Cell Adhesion Molecules
2
2019
172
0.070
 Why?
Risk Factors
1
2020
9704
0.070
 Why?
Prognosis
2
2018
3772
0.070
 Why?
Gene Expression Profiling
1
2012
1688
0.060
 Why?
Cell Cycle Proteins
2
2023
577
0.060
 Why?
Antigens, Neoplasm
2
2019
309
0.060
 Why?
CD8-Positive T-Lymphocytes
2
2023
846
0.060
 Why?
Cell Cycle
2
2018
581
0.060
 Why?
Combined Modality Therapy
2
2019
1204
0.050
 Why?
Mesylates
1
2022
7
0.050
 Why?
Signal Transduction
2
2014
4826
0.050
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2022
64
0.050
 Why?
Clinical Protocols
1
2023
252
0.050
 Why?
Ligands
1
2024
614
0.050
 Why?
RNA, Small Interfering
1
2024
571
0.050
 Why?
Chimerism
1
2021
29
0.050
 Why?
Lymphoid Tissue
1
2021
68
0.040
 Why?
Lymphocyte Subsets
1
2021
85
0.040
 Why?
Liver
1
2009
1826
0.040
 Why?
Mice, SCID
1
2021
350
0.040
 Why?
SEER Program
1
2021
206
0.040
 Why?
Hormones
1
2020
140
0.040
 Why?
Mice, Inbred NOD
1
2021
586
0.040
 Why?
M Phase Cell Cycle Checkpoints
1
2018
24
0.040
 Why?
Tissue Distribution
1
2018
291
0.040
 Why?
Infant, Newborn
1
2009
5687
0.040
 Why?
Anemia
1
2019
160
0.040
 Why?
Pregnancy
1
2009
6357
0.030
 Why?
Cetuximab
1
2016
93
0.030
 Why?
Retreatment
1
2016
69
0.030
 Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2016
114
0.030
 Why?
Neoplasm Transplantation
1
2016
258
0.030
 Why?
Drug Screening Assays, Antitumor
1
2016
195
0.030
 Why?
Platinum
1
2016
44
0.030
 Why?
Hematopoietic Stem Cell Transplantation
1
2021
572
0.030
 Why?
Transcription Factors
1
2023
1628
0.030
 Why?
History, Ancient
1
2015
52
0.030
 Why?
Proto-Oncogene Proteins p21(ras)
1
2016
258
0.030
 Why?
Databases, Genetic
1
2015
228
0.030
 Why?
DNA Damage
1
2017
364
0.030
 Why?
Mice, Knockout
1
2021
2755
0.030
 Why?
Biomarkers
2
2016
3880
0.030
 Why?
Opioid-Related Disorders
1
2021
480
0.030
 Why?
Phenotype
1
2021
3044
0.020
 Why?
Drug Combinations
1
2013
323
0.020
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2015
253
0.020
 Why?
Intracellular Signaling Peptides and Proteins
1
2015
431
0.020
 Why?
Immunohistochemistry
1
2016
1664
0.020
 Why?
Biopsy, Needle
1
2011
188
0.020
 Why?
Cohort Studies
1
2021
5388
0.020
 Why?
Enzyme Inhibitors
1
2014
809
0.020
 Why?
Transcription, Genetic
1
2017
1404
0.020
 Why?
HT29 Cells
1
2010
36
0.020
 Why?
Proto-Oncogene Proteins
1
2014
634
0.020
 Why?
ErbB Receptors
1
2013
601
0.020
 Why?
Protein-Tyrosine Kinases
1
2013
430
0.020
 Why?
Ki-67 Antigen
1
2010
107
0.020
 Why?
Patient Selection
1
2013
663
0.020
 Why?
Capillary Permeability
1
2010
131
0.020
 Why?
Follow-Up Studies
1
2018
4892
0.020
 Why?
Patient Satisfaction
1
2013
641
0.020
 Why?
Membrane Proteins
1
2015
1105
0.020
 Why?
Positron-Emission Tomography
1
2010
283
0.020
 Why?
Algorithms
1
2015
1618
0.020
 Why?
Magnetic Resonance Imaging
1
2019
3376
0.020
 Why?
Tomography, X-Ray Computed
1
2016
2523
0.020
 Why?
Adolescent
1
2024
20179
0.010
 Why?
Brain
1
2014
2620
0.010
 Why?
Young Adult
1
2014
12312
0.010
 Why?
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (284) concept(s)
_
Co-Authors Expand Description
See all (68) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)